|
|
|
|
| OTHER WSR COVERAGE SUMMARY |
NYMX Nov 4, 2003 @ $2.57
Currently $4.65 (up 81%) |
CMMD Nov 19, 2003 @ $1.03
Currently $1.12 (up 9%) |
NTDL Feb 25, 2004 @ $0.98
Currently $0.92 (down 6%) |
BPA Mar 26, 2004 @ $4.28
Currently $4.83 (up 13%)) |
In March, a wave of worldwide bearish sentiment following the terrorist attacks
in Madrid, Spain caused the deepest yet correction in the year-long bull market
in the U.S. However, despite considerable selling pressure that dominated since
the second week of March, the major stock market indexes bounced back up,
finishing the month relatively flat.
During the MONTH OF MARCH, the major indexes performed as follows:
DJIA fell 2.1% to 10,357.70 points,
NASDAQ lost 1.7% closing at 1,994.22 points,
S&P 500 dropped 1.6% to 1,126.21 points, and
RUSSELL 2000 gained 0.1% reaching 590.31 points.
The strong finish in the last few days of March pointed all of the indexes
closer to their 52-week highs, strengthening the trading range that developed
since January. But clear favorites were small cap stocks from RUSSELL 2000,
which has not corrected as sharply and recovered impressively. Assuming
favorable economic conditions, the small cap sector could lead the way in the
next surge, propelled by a search of still undiscovered undervalued issues.
April has begun with a good strong performance of markets, and economic data.
The employment statistics with announcement of over 300,000 jobs being added
during the most recent monthly period, should bode well for the markets this
month.
In March, WallStreet Research released a corporate profile featuring Spectrum
Sciences & Software Holdings Corp. (OTC BB: SPSC), an established government
contractor providing full-service, solutions, primarily to the Department of
Defense (DOD). Trading under the symbol SPSC, the Company is positioned to
capitalize on its favored defense vendor status established with the DOD and
expand its business amidst the growing worldwide demand in the nearly
recession-proof defense and national security industries. Since the release
of the WSR corporate profile featuring SPSC on March 9th, the stock advanced
over 15% closing at $2.80 on April 1st.
For more information about Spectrum Sciences & Software Holdings Corp.,
visit the Company's website at
www.specsci.com
or view the SPSC
corporate profile, including risk factors and disclaimers, at
www.WallStreetResearch.org.
|
APRIL STOCK OF THE MONTH (SPECULATIVE INVESTMENT)
On March 26th, WallStreet Research released an analyst
report initiating
coverage of BioSante Pharmaceuticals, Inc. (AMEX: BPA), an emerging
biopharmaceutical company with a late stage pipeline of gel hormone therapy
products and a proprietary nanoparticulate-based platform technology for
alternative methods of administering vaccines and other treatments.
Symptoms treated with hormone therapy in men include impotence, lack of sex
drive, muscle weakness and osteoporosis, and in women, menopausal and
postmenopausal symptoms such as hot flashes, vaginal atrophy, decreased
libido and osteoporosis. The Company’s sex-specific transdermal gel
formulations contain testosterone or estradiol, a natural form of estrogen,
as well as appropriate combinations of testosterone, estradiol and
norethindrone, a form of progestogen, another female hormone which has been
shown to reduce the potential risks of uterine hyperplasia or cancer
associated with isolated estrogen therapy. Human clinical trials have begun
on four of the Company's proposed hormone therapy products.
In a diversified platform, the Company is developing its multi-purpose
nanotechnology-based delivery system, using calcium phosphate (CAP)
nanoparticles as vehicles to administer vaccines and therapeutic drugs,
mainly proteins such as insulin, through nasal, oral and needle-free
transcutaneous routes. The Company’s vaccine adjuvant,
BioVant™, is undergoing various preclinical animal studies with
commercial partners to develop vaccines for infectious diseases, and through
Cooperative Research and Development Agreements (CRADA) with branches of the
U.S. military to produce effective biodefense vaccines against anthrax, ricin,
staph and bubonic plague. The Company also conducts partner-funded studies
with BioOral™, CAP-based method to deliver insulin and other proteins
without injection, as well as research to purify the milk of transgenic
livestock through a patented process of isolating biologically active
therapeutic proteins from their milk.
With a solid track record of raising funds and no long term debt, the Company
appears well positioned to continue its product development and advancement of
its clinical trials. In August 2003, the Company raised $10.3 million in a
private placement offering of 4.8 million units consisting of one common share
and one half warrant. As of December 31, 2003, the Company had $9.1 million
cash on hand.
The Company’s management team has a wealth of product development,
clinical and executive experience, and is led by Stephen Simes, Vice Chairman,
President and CEO, who has been successful in selling prior companies for a large
premium to corporate investors in mergers. The Company's Board of Directors is
led by Chairman Louis W. Sullivan, M.D., President Emeritus of the Morehouse School
of Medicine, Atlanta, Georgia, who served four years as Secretary of Health and
Human Services during the Bush Administration (1989-1993) and holds Director
positions on the boards of Bristol-Myers Squibb Co. (NYSE: BMY) and 3M Co. (NYSE: MMM),
among other well known companies.
Since the WallStreet Research report, the BPA stock in a few trading days reached
a high of $4.90, gaining 14% from the $4.28 report price. The Company has 14.3 million
shares outstanding and the daily average trading volume in the past three months is 131,800.
Institutions own approximately 12.1% of the outstanding shares. The high and low in a
52-week range is $7.11 and $1.85, respectively.
For more information about BioSante Pharmaceuticals, Inc., visit the company's website at
www.biosantepharma.com
or view the WSR research report, including the risk factors and
disclaimers, at
www.WallStreetResearch.org.
April 5, 2004
|
About
WallStreet Research:
WallStreet Research is a prominent research boutique formed over twenty years ago and
led by Alan Stone, Managing Director of Alan Stone & Company, LLC. The firm specializes
in the microcap and smallcap investment arena, looking for emerging growth companies
with strong management, unique or proprietary technology, significant market potential,
financial strength, and outstanding long-term earnings growth possibilities. The firm
has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known
for discovering promising companies and bringing them to the attention of the investment
community.
For more information about WallStreet Research and our complete reports, please visit our
website at
www.WallStreetResearch.org. Should you wish to receive a PDF file on WallStreet Research,
please reply to this email. In the event you wish to be removed from this database, please
reply via email with your request. Thank you for your continued interest.
|
Disclaimers:
The information presented herein or in the WallStreet Research reports is not to be construed
as an offer to sell, nor a solicitation of an offer to purchase, any securities referred to
herein or otherwise. The newsletter and research report contents are based entirely on
information available to the public and has been obtained from the company featured herein,
as well as other sources, in each case without independent verification. The information
featured herein is considered reliable, but cannot be guaranteed as to accuracy or
completeness. The information includes certain forward-looking statements within the meaning
of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or
certain risks. The reader is hereby advised to review all SEC filings for a more complete
description of the Company's business, including the financial statements and all risk factors
set forth therein. By accepting and reading this report, the reader hereby acknowledges that
neither WallStreet Research, nor any other affiliate thereof makes any representation, either
express or implied, as to the accuracy, completeness, fitness for a particular purpose or
future results, of any statement contained herein. Neither WallStreet Research, nor any of its
officers, agents or affiliates, accepts any liability whatsoever for any statements made
herein, including without limitation any liability for direct, consequential or special
damages of any kind or nature. Any securities mentioned herein may be deemed speculative, and
not appropriate or suitable for all investors, and anyone reading this report is advised to
discuss its contents with their investment advisors. The nature of the information contained
in this report is considered time sensitive, is subject to change without notice, and cannot
be relied upon after a period of three months, unless updated.
Alan Stone & Company, LLC (hereinafter "ASC"), an affiliate of WallStreet Research, receives
fees from companies mentioned herein and in the reports. ASC received $10,000 from BioSante
Pharmaceutical, Inc. for publishing and distribution of WallStreet Research analyst coverage
initiated in March 2004, and is under contract to receive $6,000 for publishing and
distribution of this electronic newsletter. ASC also is under contract to receive $6,500 from
BioSante in conjunction with a roadshow program scheduled for the week of April 12th, when the
company will be making corporate presentations in three cities. ASC received $5,000 from Teton
Petroleum Co. for publishing and distribution of the March 2004 electronic newsletter, and is
under contract to receive additional $10,000 for initiating WallStreet Research analyst
coverage on Teton Petroleum. ASC received compensation of 10,000 shares of common stock of
NuTech Digital, Inc. for publishing and distribution of the February 2004 electronic
newsletter, and additional 15,000 shares of common stock of NuTech Digital, Inc. for
publishing and distribution of WallStreet Research analyst coverage initiated in February
2004, and has an agreement to earn up to 100,000 stock options to purchase common stock in
NuTech Digital, Inc. for newsletter and research services. ASC has earned compensation in the
last two years for organizing roadshows and meetings on behalf of Command Security
Corporation, and received $5,000 for update of WallStreet Research analyst report in November
2003, and is under contract to receive $5,000 to update the WallStreet Research report for
current developments. ASC or its affiliates may also own other shares of companies mentioned
herein or in the reports, for investment purposes, in its corporate accounts, and may increase
or decrease its positions at any time, without notice.
|
|
WALLSTREET
RESEARCH
New York City, Los Angeles
Palm Beach
www.WallStreetResearch.org
|
|
Contact info:
Alan Stone, Managing Director WallStreet Research
Solutions for Emerging Companies™
590 Madison Ave, 21st floor
New York, NY 10022
212.521.4102
|
|
|
|
|
|